Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320253 | 0.82 | TLR4 (0.56) | TLR4MT-CO2ALOX5 | |
| SCHEMBL9014001 | 0.82 | TLR4 (0.45) | TLR4NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL5684616 | 0.79 | TLR4 (0.49) | TLR4NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL2431325 | 0.77 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2LMNAGAA | |
| SCHEMBL6907551 | 0.76 | TLR4 (0.47) | TLR4MT-CO2ALOX5 | |
| SCHEMBL7910636 | 0.75 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2LMNAGAA | |
| SCHEMBL28299070 | 0.75 | TLR4 (0.41) | TLR4 | |
| SCHEMBL11065128 | 0.74 | TLR4 (0.54) | TLR4ALOX5 | |
| SCHEMBL9190051 | 0.74 | TLR4 (0.44) | TLR4LMNAMT-CO2ALOX5 | |
| SCHEMBL10810560 | 0.73 | TLR4 (0.63) | TLR4NPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8465674-B2 | Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition | JNC CORPORATION (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20120145959-A1 | DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145959-A1 | DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION | DCUN1D2, OCIAD1, CPNE4 | TLR4 4459/4885NPC1 845/4885RAB9A 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.